Subject(s)
Acetaminophen/adverse effects , Anal Canal/pathology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Drug Overdose/complications , Rectum/pathology , Acetaminophen/administration & dosage , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Female , Humans , Necrosis/chemically induced , SuppositoriesSubject(s)
Benzodiazepines/pharmacology , Carbamazepine/pharmacology , Drug Hypersensitivity/etiology , Adult , Benzodiazepines/adverse effects , Benzodiazepines/immunology , Carbamazepine/adverse effects , Carbamazepine/immunology , Cross Reactions , Drug Hypersensitivity/immunology , Drug Interactions , Humans , Male , OlanzapineSubject(s)
Anti-Bacterial Agents/adverse effects , Exanthema/chemically induced , Pristinamycin/adverse effects , Adult , Anti-Bacterial Agents/administration & dosage , Diagnosis, Differential , Erysipelas/drug therapy , Exanthema/diagnosis , Female , Humans , Pityriasis Rosea/diagnosis , Pristinamycin/administration & dosage , Torso/pathologySubject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects , Esomeprazole/adverse effects , Lupus Erythematosus, Cutaneous/chemically induced , Proton Pump Inhibitors/adverse effects , 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Adult , Autoantibodies/blood , Biopsy , Diagnosis, Differential , Esomeprazole/therapeutic use , Female , Gastroesophageal Reflux/drug therapy , Humans , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/pathology , Male , Middle Aged , Pantoprazole , Pregnancy , Proton Pump Inhibitors/therapeutic use , Skin/pathologySubject(s)
Aminoquinolines/adverse effects , Antineoplastic Agents/adverse effects , Immunologic Factors/adverse effects , Mental Disorders/chemically induced , Aged, 80 and over , Aminoquinolines/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Dementia/chemically induced , Depression/chemically induced , Female , Humans , Imiquimod , Immunologic Factors/therapeutic use , Male , Middle Aged , Psychomotor Agitation/etiology , Skin Neoplasms/drug therapy , Sleep Initiation and Maintenance Disorders/chemically inducedABSTRACT
No disponible
Subject(s)
Humans , Cross Reactions/immunology , Carbamazepine/adverse effects , Drug Hypersensitivity/immunology , Antipsychotic Agents/adverse effects , Risk Factors , Drug Interactions/immunologySubject(s)
Cutaneous Fistula/chemically induced , Intestinal Fistula/chemically induced , Nicorandil/adverse effects , Oral Ulcer/chemically induced , Skin Ulcer/chemically induced , Vasodilator Agents/adverse effects , Biotransformation , Health Surveys , Humans , Incidence , Nicorandil/pharmacokinetics , Oral Ulcer/epidemiology , Pharmacovigilance , Prospective Studies , Vasodilator Agents/pharmacokineticsSubject(s)
Alanine/analogs & derivatives , Amyloid Precursor Protein Secretases/antagonists & inhibitors , Azepines/adverse effects , Nootropic Agents/adverse effects , Psoriasis/chemically induced , Adrenal Cortex Hormones/therapeutic use , Aged , Alanine/adverse effects , Alanine/pharmacology , Alanine/therapeutic use , Alzheimer Disease/complications , Alzheimer Disease/drug therapy , Azepines/pharmacology , Azepines/therapeutic use , Clinical Trials, Phase III as Topic , Drug Therapy, Combination , Early Termination of Clinical Trials , Female , Humans , Keratinocytes/drug effects , Keratinocytes/metabolism , Memantine/therapeutic use , Models, Biological , Nootropic Agents/pharmacology , Nootropic Agents/therapeutic use , Phenylcarbamates/therapeutic use , Psoriasis/complications , Psoriasis/drug therapy , Receptors, Notch/physiology , Rivastigmine , Signal Transduction/drug effectsSubject(s)
Drug Eruptions/diagnosis , HIV Infections/complications , Silicone Oils/adverse effects , Adult , Buttocks , Cosmetic Techniques/adverse effects , Dermatomycoses/diagnosis , Diagnosis, Differential , Drug Contamination , Drug Eruptions/etiology , Drug Eruptions/pathology , Erythema/diagnosis , Histiocytes/pathology , Humans , Injections , Male , Psoriasis/diagnosis , Silicone Oils/administration & dosage , Skin Diseases, Genetic/diagnosisABSTRACT
BACKGROUND: Mammalian target of rapamycine (mTOR) inhibitors are being increasingly prescribed as antitumoural drugs, and associated adverse cutaneous effects are frequent but poorly described. The aim of this study was to describe such adverse effects and to assess the quality of life of patients experiencing them. PATIENTS AND METHODS: Over a period of 18 months, 18 patients treated with mTOR inhibitors for renal carcinoma were included and 77 dermatological examinations performed. Wherever a cutaneous adverse event was present, quality of life was evaluated using the Skindex 30 questionnaire. RESULTS: Fifteen of the 18 patients included presented adverse cutaneous events, consisting of buccal ulcers (61.1%), xerosis (55.5%), distal onycholysis (50%), acneiform eruption (38.8%), paronychia (22.2%) and pruritus (22.2%). Buccal ulcerations and perionyxis had an especially marked impact on quality of life, which was greatest in terms of physical score (19%), followed by emotional (9%) and functional (6%) scores. CONCLUSION: Cutaneous adverse effects of mTOR inhibitors are frequent and have a considerable impact on quality of life, particularly as regards physical scores. Dermatological examination appears useful to allow early management of cutaneous adverse effects and improve the quality of life of these patients.